000			01157 a2200301 4500
005			20250513160010.0
264		0	_c19990219
008			199902s 0 0 eng d
022			_a0037-1963
040			_aNLM _beng _cNLM
100	1		_aWarkentin, T E
245	0	0	_aLimitations of conventional treatment options for heparin-induced thrombocytopenia. _h[electronic resource]
260			_bSeminars in hematology _cOct 1998
300			_a17-25; discussion 35-6 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
650	0	4	_aAncrod _xtherapeutic use
650	0	4	_aAnticoagulants _xtherapeutic use
650	0	4	_aChondroitin Sulfates _xtherapeutic use
650	0	4	_aDermatan Sulfate _xtherapeutic use
650	0	4	_aDrug Combinations
650	0	4	_aHeparin _xadverse effects
650	0	4	_aHeparin, Low-Molecular-Weight _xtherapeutic use
650	0	4	_aHeparitin Sulfate _xtherapeutic use
650	0	4	_aHumans
650	0	4	_aThrombocytopenia _xchemically induced
650	0	4	_aWarfarin _xadverse effects
773	0		_tSeminars in hematology _gvol. 35 _gno. 4 Suppl 5 _gp. 17-25; discussion 35-6
999			_c9818266 _d9818266